Format

Send to

Choose Destination
Neurobiol Dis. 2014 Dec;72 Pt A:117-22. doi: 10.1016/j.nbd.2014.05.001. Epub 2014 May 10.

Early detection of Alzheimer's disease using PiB and FDG PET.

Author information

1
Department of Psychiatry, University of Pittsburgh School of Medicine, USA. Electronic address: cohenad@upmc.edu.
2
Department of Psychiatry, University of Pittsburgh School of Medicine, USA; Department of Neurology, University of Pittsburgh School of Medicine, USA.

Abstract

Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has become of central importance following publication of the NIA-Alzheimer's Association revised criteria for the diagnosis of AD, mild cognitive impairment (MCI) and preclinical AD. The use of in vivo amyloid imaging agents, such a Pittsburgh Compound-B and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) is able to detect early AD pathological processes and subsequent neurodegeneration. Imaging with PiB and FDG thus has many potential clinical benefits: early or perhaps preclinical detection of disease and accurately distinguishing AD from dementias of other etiologies in patients presenting with mild or atypical symptoms or confounding comorbidities in which the diagnostic distinction is difficult to make clinically. From a research perspective, this allows us to study relationships between amyloid pathology and changes in cognition, brain structure, and function across the continuum from normal aging to MCI to AD. The present review focuses on use of PiB and FDG-PET and their relationship to one another.

KEYWORDS:

Alzheimer's disease; Amyloid; FDG; Glucose metabolism; Neuroimaging; Pittsburgh compound B

PMID:
24825318
PMCID:
PMC4226742
DOI:
10.1016/j.nbd.2014.05.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center